dacarbazine has been researched along with Carcinoma, Ehrlich Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, LN; Chammas, R; de Oliveira, SI; Fernandes, PD; Jancar, S; Nonogaki, S; Onuchic, AC; Pinheiro, MC; Rohde, CB | 1 |
| Dimitriadis, K; Schmidt, CG; Schütte, J; Seeber, S | 1 |
2 other study(ies) available for dacarbazine and Carcinoma, Ehrlich Tumor
| Article | Year |
|---|---|
Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Carcinoma, Ehrlich Tumor; Caspase 3; Cell Proliferation; Cyclooxygenase 2; Dacarbazine; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Galectin 3; Immunohistochemistry; Macrophages; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neovascularization, Pathologic; Nitric Oxide; Phenotype; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Signal Transduction; Time Factors; Triazoles; Tumor Burden; Vascular Endothelial Growth Factor A | 2010 |
Experimental basis and clinical experience with non-cross-resistant combinations in solid tumours.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Ehrlich Tumor; Carcinoma, Small Cell; Cell Line; Cisplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug Resistance; Etoposide; Humans; Ifosfamide; Male; Naphthacenes; Sarcoma; Teratoma; Testicular Neoplasms; Vinca Alkaloids; Vincristine | 1984 |